Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Emmecell Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, GABEL, GAILENE, and is in 1 distinct art unit.
GABEL, GAILENE is the busiest examiner for the company, with 1 pending office action. This single action represents the total active prosecution for Emmecell Inc. in the Biotechnology & Pharmaceuticals field. The 1 distinct art unit indicates a specific technical focus for the company's current filing.
The prosecution is concentrated under 1 distinct examiner. Practitioners can focus on the specific examination style of GABEL, GAILENE. With only 1 pending office action, the company's immediate patent success in the Biotechnology & Pharmaceuticals sector depends on this single matter in 1 distinct art unit. A successful outcome in this 1 pending office action is essential for the company's current patent strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GABEL, GAILENE | 1 | 75.6% | +44.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18362678 | IDENTIFICATION AND ISOLATION OF HUMAN CORNEAL ENDOTHELIAL CELLS (HCECS) | GABEL, GAILENE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18362678 | IDENTIFICATION AND ISOLATION OF HUMAN CORNEAL ENDOTHELIAL CELLS (HCECS) | GABEL, GAILENE | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18362678 | IDENTIFICATION AND ISOLATION OF HUMAN CORNEAL ENDOTHELIAL CELLS (HCECS) | GABEL, GAILENE | 1678 | §102§112Other | Non-Final OA | — | Pending | Jul 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEmmecell Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Gailene Gabel has the most, with 1 of Emmecell Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
